WHO urgently seeks more resources as DRC Ebola outbreak outpaces response

In Geneva, the World Health Organization delivered an urgent message: the Ebola outbreak spreading through the Democratic Republic of Congo is moving faster than anyone can contain it. The virus has infected 3,802 people and killed 1,707 in less than three months—making this the largest outbreak the country has ever seen. WHO spokesman Tarik Jasarevic told reporters the organization needs more money, more staff, more of everything. "The outbreak is unfortunately still expanding beyond the capacity of the response," he said. What the world is facing is not a slow-burning crisis that can be managed with existing resources. It is an accelerating one.

The scale of the outbreak is staggering. Of the 3,802 confirmed cases, 727 patients have recovered. Another 275 cases are suspected and under investigation. Health workers are tracking 17,000 contacts of infected people, checking on more than 80 percent of them daily. The virus has been reported in five provinces, but nearly 90 percent of cases are concentrated in the northeastern Ituri province, with most of the remainder in the neighboring North Kivu region. This geographic clustering offers some hope for containment—but only if resources arrive fast enough.

What makes this outbreak particularly difficult is the strain itself. The virus belongs to the Bundibugyo species of Ebola, a variant for which there are no proven treatments, no vaccines, and no preventive drugs. Unlike the Zaire strain that has caused previous outbreaks, Bundibugyo has left doctors and researchers without established tools. Jasarevic emphasized that the response must focus not only on where cases are appearing now, but on predicting where the virus might spread next—a task that requires field investigation teams, safe burial teams, and community workers on the ground. The WHO is asking for resources to scale up treatment capacity across all these areas.

But the scientific community is not standing still. Multiple trials are underway to find solutions. Vasee Moorthy, who leads the WHO's research and development efforts, said early results are encouraging. Researchers are testing whether the Ervebo vaccine, which protects against the Zaire species, might also work against Bundibugyo. A WHO vaccine advisory group reviewed new animal data on Friday and is expected to issue recommendations this week. Two candidate vaccines are moving into human trials. The University of Oxford and the Serum Institute of India are testing a vaccine using the ChAdOx1 platform; the first Phase I trial began in Britain on July 24. Moderna is running parallel trials of an mRNA-based vaccine in Canada, also starting this week. Both are being tested simultaneously in animals and in human volunteers to assess immune response and safety.

Meanwhile, treatment trials are running in Ituri itself. Doctors are testing two potential therapies on confirmed Ebola patients: a monoclonal antibody called MBP134 and the antiviral drug remdesivir, both separately and in combination. A separate trial is evaluating obeldesivir, an oral antiviral, in people who have been exposed to confirmed cases. More than 25 high-risk contacts have enrolled in that trial, taking the drug for ten days to see whether it can prevent infection from taking hold. The logic is straightforward: if an oral medicine can stop disease from developing in exposed people, it could become a crucial tool for containing spread.

The outbreak was officially declared on May 15 after deaths were reported in Ituri. In the three months since, it has become the DRC's 17th Ebola outbreak—and by far the largest. The virus spreads through close contact and infected bodily fluids, making it particularly dangerous in settings where burial practices involve direct contact with the deceased, where families care for sick relatives without protective equipment, and where health systems are already stretched thin. The WHO's call for more resources is not a request for nice-to-have additions. It is a statement that without immediate, substantial support, the outbreak will continue to outpace the ability to stop it.